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Abstract
Heat shock protein 90 (HSP90), one of the most abun-
dant proteins in the cardiac cells is essential for cell 
survival. Previous studies have shown that angio-
tensin II induces cardiac cell hypertrophy. However, 
the role of HSP90 in the angiotensin II-induced cardiac 
hypertrophy is unclear. In this study, we showed that 
HSP90 regulated angiotensin II-induced hypertrophy 
via maintenance of the IκB kinase (IKK) complex stabil-
ity in cardiac cells. An HSP90 inhibitor, geldanamycin 
(GA), significantly suppressed angiotensin II-induc-
ed [3H]leucine incorporation and atrial natriuretic fac-
tor expression in cardiac cells. GA also inhibited the 
NF-κB activation induced by angiotensin II. Impor-
tantly, treatment with GA caused a degradation of 
IKKα/β; on the other hand, a proteasome-specific in-
hibitor restored the level of IKKα/β. We also found that 
GA prevented HSP90-IKKs complex induced by angio-
tensin II in cardiac cells. The small interfering RNA 
(siRNA)-mediated knockdown of HSP90 expression 
significantly inhibited angiotensin II-induced cell hy-
pertrophy and NF-κB activation. These results sug-
gest that angiotensin II-induced cardiac hypertrophy 
requires HSP90 that regulates the stability and com-
plex of IKK.
Keywords: angiotensin II; cardiomyopathy, hyper-
trophic; geldanamycin; HSP90 heat-shock proteins; 
IκB kinase; NF-κB
Introduction
Cardiac hypertrophy is an increase in the size of 
cardiac myocytes to generate greater muscle 
mass, usually driven by a larger workload for the 
heart (Heineke et al., 2006). Although it is an 
adaptive response to physical exercise, excessive 
hypertrophy can result in arrhythmia, dilated 
cardiomyopathy, fibrotic disease, heart failure, and 
sudden death (Marian and Roberts, 1995). Cardiac 
hypertrophy is induced by various vasoactive 
peptides, cytokines, and several neurohormones 
such as epinephrine, norepinephrine, and aldo-
sterone (Frey and Olson, 2003). Angiotensin II, a 
vasoactive octapeptide, is an important humoral 
factor responsible for cardiac hypertrophy (Kim and 
Iwao, 2000). Numerous studies have shown that 
angiotensin II induces nuclear factor-κB (NF-κB) 
activation in cultured cardiac cells (Brasier et al., 
2000; Kim and Iwao, 2000) and reported that the 
activation of NF-κB is required for hypertrophic 
responses from primary rat neonatal ventricular 
cardiomyocytes (Purcell et al., 2001; Li et al., 
2004). NF-κB is a ubiquitously expressed cy-
toplasmic transcription factor whose primary mode 
of regulation is through nuclear translocation. The 
most abundant form of NF-κB transcription factor 
is heterodimer of p65 and p50 in several family 
members (Pereira and Oakley, 2008). The NF-κB 
p65 subunit is sequestered in the cytoplasm by 
interaction with the inhibitor of κB (IκB). If cells are 
stimulated by several factors, phosphorylation of 
IκBα leads to its ubiquitination and degradation, 
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Figure 1. Effect of geldanamycin on angiotensin II-induced cellular hy-
pertrophy in rat cardiomyocytes. (A) Cardiac cells were treated with an-
giotensin (Ang II) for 24 h with pulsed addition of [3H]leucine for the final 
4 h. At the end of labeling, cells were washed with PBS and treated with 
5% trichloroacetic acid for 30 min. An aliquot was taken to determine the 
incorporated radioactivity by liquid scintillation counting. *P＜ 0.01 com-
pared to control. (B) Cardiac cells were pretreated with geldanamycin 
(GA) for 2 h. Then cells were stimulated with angiotensin II (1 μM) for 24 
h with pulsed addition of [3H]leucine for the final 4 h. *P＜ 0.01 com-
pared to angiotensin II (1 μM) alone. (C) Cardiac cells were pretreated 
with GA (1 μM) for 2 h prior to stimulation of the cells with angiotensin II 
(1 μM) for 24 h. Immunocytochemistry assay was performed using an-
ti-atrial natriuretic factor (ANF) antibody. (D) Cardiac cells were pre-
treated with geldanamycin (GA, 1 μM) for 2 h. Then cells were stimulated 
with angiotensin II (1 μM) for 24 h. The relative cell surface area was an-
alyzed using NIH image software. The results represent the means of 
three independent experiments in which 50 cells were counted in each 
experiment. *P＜ 0.01 compared to control. **P＜ 0.01 compared to 
angiotensin II (1 μM) alone.
permitting NF-αB to translocate to the nucleus 
(Pereira and Oakley, 2008). One of the best-known 
pathways of IκBα phosphorylation is activation of 
IκB kinase (IKK) complex, which is composed of 
IKKα/β  and IKKγ, and these possess essential 
kinase activity to phosphorylate IκB (Luo et al., 
2005).
    Recent studies have demonstrated that heat 
shock proteins (HSPs) are involved in cardiac 
hypertrophy induced by a wide variety of stimuli. 
The cardiotrophin-1 (CT-1), an interleukin-6 family 
cytokine causes an increase of HSP56 expression 
leading to cellular hypertrophy in cardiac myocytes 
(Railson et al., 2001). HSP27 regulates the change 
of muscle mass induced by mechanical load in rat 
hind limb models (Kawano et al., 2007). Recent 
data using animal models indicate that HSP70 also 
regulates cardiac hypertrophy via several me-
chanisms (Kim et al., 2006; Kee et al., 2008). 
Interestingly, HSPs have been found to be a 
regulator of NF-κB cascade in inflammation 
induced by angiotensin II (Zhou et al., 2005; Chen 
et al., 2006). However, it is still unclear whether 
HSP90 is associated with NF-κB cascade in the 
modulation of cardiac cell hypertrophy induced by 
angiotensin II. In this study, we investigated the 
role of HSP90 on NF-κB activation pathway in 
angiotensin II-induced cardiac cell hypertrophy. 
Results
HSP90 inhibitor suppressed angiotensin II-induced 
cardiac cell hypertrophy 
To confirm the hypertrophic effect of angiotensin II 
in cardiac cells, [3H]leucine incorporation assay 
was examined in rat neonatal cardiac myocytes. 
Cardiac cells were treated with angiotensin II (0.1 
nM-1 μM) for 24 h. Angiotensin II increased 
[3H]leucine incorporation in a concentration-de-
pendent manner in cardiac myocytes (Figure 1A). 
A similar result was obtained using the assessment 
of the ratio of total protein to DNA content (data not 
shown). To determine whether HSP90 modulates 
angiotensin II-induced cardiac hypertrophy, we 
primarily utilized the HSP90-specific inhibitor, gel-
danamycin (GA). Cardiac cells were pretreated 
with various concentration of GA for 2 h prior to 
stimulation of the cells with angiotensin II for 24 h. 
As shown in Figure 1B, angiotensin II-induced 
[3H]leucine incorporation was inhibited by GA in a 
concentration-dependent manner. The specific 
marker of hypertrophy, the artrial natriuretic factor 
(ANF), was also visualized by immunocytoche-
mical staining assay. GA treatment significantly 
decreased the ANF level in cells, while ANF was 
detected around the nucleus in the angiotensin 
II-treated group compared with untreated cells 
(Figure 1C). Angiotensin II also increased cell size, 
a characteristic feature of hypertrophic response, 
in cardiac cells, an effect that was significantly 
inhibited by GA treatment (Figure 1D). The same 
results were observed even when GA derivative 
17-(a l ly lam ino)-17-demethoxygeldanamycin 
(17-AAG), another HSP90 inhibitor, was used in 
place of GA (data not shown).
Effect of HSP90 inhibitor on angiotensin II-induced 
NF-κB activation in cardiac cells
To assess whether HSP90 regulates the NF-κB 
activation, we examined the nuclear translocation 
of NF-κB p65 subunit and NF-κB luciferase 
activity. Angiotensin II stimulated the nuclear 
translocation of p65 NF-κB in cardiac cells (Figure 
2A). NF-κB luciferase activity was also enhanced 
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Figure 2. Effect of geldanamycin on the NF-κB activation. (A) Cardiac 
cells were treated with angiotensin II (Ang II) for 1 h. Nuclear extracts 
were prepared and equal amounts of protein were separated by SDS-PAGE
gel. The nuclear translocation of NF-κB was visualized by immunoblot 
assay using anti-p65 NF-κB antibody. (B) After transfection with 100 ng 
of pNF-κB/LUC luciferase vector for 24 h, cells were treated with angio-
tensin II for 6 h. Luciferase activity was determined using Luciferase 
Reporter Assay Kit. (C) Cardiac cells were pretreated with geldanamycin
(GA) for 2 h. Then cells were incubated with angiotensin II (1 μM) for 1 h. 
Equal amounts of nuclear protein were separated by SDS-PAGE gel, and 
nuclear translocation of NF-κB was detected using an anti-p65 NF-κB 
antibody. (D) After transfection with pNF-κB/LUC luciferase vector for 24 
h, cells were pretreated with GA for 2 h prior to angiotensin II (1 μM) 
treatment for 6 h. Nuclear translocation of NF-κB was detected using an 
anti-p65 NF-κB antibody. (E) Cardiac cells were pretreated with GA (1 
μM) or HSP70 inhibitor (Hsp70i, 100 μM) for 2 h. Then cells were in-
cubated with angiotensin II (1 μM) for 1 h. Nuclear translocation of 
NF-κB was detected using an anti-p65 NF-κB antibody. The results rep-
resent the means of three independent experiments.
Figure 3. Effect of geldanamycin on IKK complex and stability. (A) 
Cardiac cells were pretreated with geldanamycin (GA) for 2 h. Then cells 
were incubated with angiotensin II (Ang II, 1 μM) for 1 h. Equal amounts 
of protein were separated by SDS-PAGE gel, and immunoblot analysis 
was performed. (B) Cardiac cells were exposed to angiotensin II (1 μM) 
for 1 h with or without pretreatment with GA (1 μM) and/or MG132 (10 
μM) for 2 h. Equal amounts of protein were separated by SDS-PAGE gel, 
and immunoblot analysis was performed using anti-IKKα/β antibody. 
Each signal was quantified by scanning densitometry and the graph 
shows the levels of each activity as relative value. Data are averages of 
three independent experiments. (C) Cardiac cells were pretreated with 
GA for 2 h. Then cells were incubated with angiotensin II (1 μM) for 1 h. 
Cell extracts were immunoprecipitated with anti-IKKα/β or anti-HSP90 
antibodies. Immunoprecipitant samples were analyzed by immunoblot 
assay with anti-HSP90, anti-IKKα/β, anti-IKKγ, or anti-cdc37 antibodies.
by the addition of angiotensin II in a con-
centration-dependent manner (Figure 2B). However, 
cardiac cells treated with GA showed that nuclear 
translocation of p65 NF-κB was decreased in a 
concentration-dependent manner (Figure 2C). The 
NF-κB luciferase activity decreased with the same 
trend as the result in Figure 2C (Figure 2D). The 
inhibitor of HSP70 did not affect the NF-κB 
activation; more precisely, it was slightly increased 
by the HSP70 inhibitor (Figure 2E). These data 
show that HSP90 might be an important regulator 
of the NF-κB pathway in angiotensin II-induced 
hypertrophy in cardiac cells.
Effect of HSP90 inhibitor on IKK complex and stability
In the classical NF-κB activation pathway, the IKK 
complex is activated, which subsequently initiates 
phosphorylation of the IκBα  (Luo et al., 2005). We 
assessed the effect of GA on IκBα  phosphorylation 
induced by angiotensin II in cardiac cells. As 
shown in the top panel of Figure 3A, the 
pretreatment of GA to cardiac cells inhibited 
angiotensin II-induced IκBα  phosphorylation. In-
terestingly, in the presence of GA, the levels of 
phospho-IKKα /β  and total IKKα /β  decreased 
(Figure 3A, middle panel). However, GA did not 
affect IKKα /β  transcription (data not shown). This 
result may imply that a level of IKKα /β  decreased 
by GA is involved in proteasomal degradation. In 
fact, the protein level of IKKα /β  is restored with a 
treatment of proteasome inhibitor MG-132 (Figure 
3B). The interaction of HSP90 with IKK complex is 
possibly an important factor for IKKs stability. 
Recent studies also have demonstrated that 
HSP90 is associated with IKKs (Broemer et al., 
2004; Pittet et al., 2005). We examined whether 
the interaction of HSP90 with IKKs is altered by GA 
treatment in cardiac cells. When cardiac cells were 
stimulated with angiotensin II, HSP90 interacted 
with IKKα /β  and IKKγ (Figure 3C). However, as 
shown in Figure 3C, the interaction between 
HSP90 and IKK complex was reduced in GA- 
treated cardiac cells. The interaction between 
HSP90 and IKKγ was also reduced when cardiac 
cells were treated with GA. The interaction bet-
ween HSP90 and cdc37 was not changed (Figure 
3C). Immunoprecipitation with control IgG revealed 
no detectable interaction of IKK complex or HSP90 
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Figure 4. Effect of HSP90 knockdown on angiotensin II-induced cellular 
hypertrophy in cardiac cells. (A) Cells were transfected with 30 nM of 
HSP90 siRNA. After 48 h, the levels of HSP90α and HSP90β were ana-
lyzed with anti-HSP90α and anti-HSP90β antibodies. (B) After 48 h of 
transfection with siRNAs, cells were treated with 1 μM of angiotensin II 
for 24 h. Immunocytochemistry assay was performed using anti-β-tubulin 
antibody. The relative cell surface area was analyzed using NIH image 
software. The results represent the means of three independent experi-
ments in which 50 cells were counted in each experiment. *P＜ 0.01 
compared to control. **P＜ 0.01 compared to angiotensin II (1 μM). (C) 
Total protein and DNA contents of cells were measured using BCA assay 
and Hoechst 33258, respectively. The results represent the means of 
three independent experiments. *P＜ 0.01 compared to control. **P＜
0.01 compared to angiotensin II (1 μM). (D) After 48 h of transfection with 
siRNA, cells were treated with 1 μM of angiotensin II for 1 h. Nuclear 
translocation of NF-κB was detected using an anti-p65 NF-κB antibody.
(data not shown).
Effect of HSP90 siRNA on angiotensin II-induced 
cardiac cell hypertrophy
We confirmed the effect of HSP90 on angiotensin 
II-induced cardiac cell hypertrophy using gene 
silencing method with small interfering RNA 
(siRNA) targeting HSP90. Knockdown of HSP90 
with siRNA was confirmed by immunoblot analysis 
(Figure 4A). Exposure of cells to both scrambled 
siRNA and HSP90 siRNAs had no effect on cell 
viability or cellular senescence (data not shown). 
Treatment of HSP90 siRNA blocked the cell size 
increase induced by angiotensin II (Figure 4B). A 
same result was also obtained using the as-
sessment of the ratio of total protein to DNA 
content (Figure 4C). As shown in Figure 4D, 
nuclear translocation of p65 NF-κB stimulated by 
angiotensin II was significantly decreased in the 
cells transfected with HSP90 siRNA compared to 
the scrambled control siRNA transfected-cells. 
These results suggest that HSP90 plays a critical 
role in angiotensin II-induced cardiac cell hyper-
trophy.
Discussion
Cellular hypertrophy is an adaptive process for 
synthesizing proteins without DNA replication, 
leading to protein accumulation (Hannan et al., 
2003). Several investigations recently have im-
plicated NF-κB activation as a classical event of 
inflammation response that is critical to the cardiac 
hypertrophic response (Brasier et al., 2000; Purcell 
et al., 2001). In addition, NF-κB plays an important 
role in cardiac hypertrophy induced by angiotensin 
II (Li et al., 2004; Freund et al., 2005). 
    In this study, we have investigated the re-
quirement of HSP90 for NF-κB activation in 
angiotensin II-induced cardiac cell hypertrophy. 
The study’s major finding is that the HSP90 
inhibitor, geldanamycin (GA), prevents angiotensin 
II-induced cardiac cell hypertrophy by blocking the 
NF-κB activation signal. Moreover, GA decreases 
the IKKα /β  stability and blocks the interaction of 
HSP90 with IKK complex in response to an-
giotensin II. Although several examples of evi-
dence on the roles of HSP90 in the NF-κB 
pathway have been reported recently (Arthur et al., 
2007; Ammirante et al., 2008), the crosstalk 
between HSP90 and the NF-κB signaling cascade 
in cardiac hypertrophy induced by angiotensin II 
remains unclear. In the present work, accompanied 
by cellular hypertrophic events, angiotensin II 
activated the NF-κB signaling cascade such as 
IKKs activation and NF-κB nuclear translocation, 
which finding is consistent with previous studies. 
However, GA inhibited this NF-κB signaling 
cascade and hypertrophic event induced by an-
giotensin II in cardiac cells. GA is an HSP90- 
specific inhibitor that binds within the ATP- 
associated pocket of HSP90 (Piper, 2001). HSP90 
has been shown to regulate many intracellular 
proteins called client proteins for HSP90 (Zhao and 
Houry, 2007). GA abolishes the interactions 
between these client proteins and HSP90, lowering 
their stability (Piper, 2001; Sharp and Workman, 
2006). In our study, as Figure 3A and B shows, 
protein levels of IKKα /β  were increased in 
angiotensin II-treated cardiac cells, but none of 
their mRNA levels of IKKα /β  changed (data not 
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shown). However, GA significantly decreased the 
IKKα /β  levels in cells stimulated by angiotensin 
(Figures 3A and B). As a consequence, the 
phosphorylation of IκBα  decreased following GA 
treatment. On the other hand, MG-132 treatment 
restored the protein levels of IKKα /β  (Figure 3B), 
suggesting that GA degraded IKKα /β  via the 
ubiquitin-proteasome pathway. It is possible that 
HSP90 affects the IKK complexes’ stability by 
interacting with them. Pittet et al. have shown that 
GA increased the IKK complex’s insolubility and 
degradation, and that exposure to GA reduced the 
interaction between HSP90 and IKKα  (Pittet et al., 
2005). In the present study, HSP90 strongly 
interacted with the IKK complex in angiotensin 
II-treated cardiac cells (Figure 3C). However, GA 
treatment dramatically reduced the interaction 
between HSP90 and the IKK complex. These 
results suggest that HSP90 is directly associated 
with the IKK complex and that this interaction 
contributes to the IKKs’ stabilization and activation, 
leading to NF-κB activation-mediated cardiac 
hypertrophy in response to angiotensin II. Mean-
while, the interaction between HSP90 and cdc37 
did not change when cardiac cells were treated 
with GA (Figure 3C). Recently, Zhang et al. 
demonstrated that GA did not change the 
HSP90-cdc37 interaction in pancreatic cells 
(Zhang et al., 2008). Their study sought to identify 
a novel HSP90 inhibitor to disrupt the HSP90- 
Cdc37 interaction. No GA changed the HSP90- 
cdc37 interaction, but celastrol treatment signifi-
cantly reduced the HSP90-cdc37 complex, which 
suggests that GA cannot disrupt the HSP90-cdc37 
interaction (Zhang et al., 2008). Also, HSP90 is 
stably associated with the cdc37 for IKK recruit-
ment and NF-κB activation (Chen et al., 2002). 
Thus, it is conceivable that the complex formation 
with HSP90-Cdc37 is a prerequisite for the IKK 
complex’s interaction with HSP90 in angiotensin 
II-induced cardiac hypertrophy. 
    Because GA, an HSP90 inhibitor, is known to 
induce HSP70 expression in cardiac tissue (Kiang 
et al., 2006), we clarified the specific role of HSP90 
in angiotensin II-induced cell hypertrophy using the 
siRNA-mediated HSP90 knockdown method. Knock-
ing down endogenous HSP90 totally eliminated 
angiotensin II-induced cell hypertrophy and nuclear 
translocation of p65 NF-κB in cardiac cells (Figure 
4). Recently, HSP70 has been found to be a novel 
regulator of cardiac hypertrophy (Kim et al., 2006; 
Kee et al., 2008) and the NF-κB pathway’s 
activation (Zheng et al., 2008). In line with this, our 
results show that the HSP70 inhibitor slightly 
increased nuclear translocation of p65 NF-κB 
(Figure 2E). Evidence also suggests that heat 
shock factor 1 (HSF1) known, as a transcription 
factor of HSP70 and HSP90, regulates cardiac 
hypertrophy (Sakamoto et al., 2006). 
    Because HSP90 also cooperates simultaneously 
with several cellular signaling pathways, it might 
affect intracellular proteins involved in cardiac 
hypertrophy. Angiotensin II also activates many 
cellular signaling pathways, such as NADPH 
oxidase, MAP kinases, protein phosphatase cal-
cineurin, and calcium channel, that are implicated 
in cardiac hypertrophy (Schluter and Wenzel, 
2008; Do et al., 2009). Cardiac hypertrophy is likely 
the result of cooperation of several signaling 
pathways, rather than a single pathway; and 
among several signaling pathways, the NF-κB 
signaling cascade plays a pivotal role in an-
giotensin II-induced cardiac hypertrophy (Freund et 
al., 2005; Kawano et al., 2005). Taken together, 
these results suggest that different HSPs, including 
HSP90, regulate signaling pathways involved in 
cardiac hypertrophy through their different distinct 
roles. Although experimental evidence on each 
HSP’s biochemical roles has accumulated, it 
remains unclear how crosstalk between HSPs and 
the signaling network is regulated during cardiac 
hypertrophy under physiologic and pathologic 
conditions. Future studies need to clarify the 
signaling network between the NF-κB pathway 
and other cellular signal factors and to elucidate 
the HSPs roles’ in this network stimulated by 
angiotensin II, leading to cardiac hypertrophic 
processes.
    Numerous studies have shown that the direct 
effect of angiotensin II on cardiac hypertrophy is 
mediated mainly via the angiotensin II type 1 
receptor (AT1R) (Zhu et al., 2003). An important 
link between angiotensin II and cardiac hyper-
trophy is NF-κB, activated mainly via AT1R by 
angiotensin II stimulation (Kalra et al., 2002). On 
the other hand, many reports on the angiotensin II 
type 2 receptor’s (AT2R) ambiguous role have 
emerged stating that AT2R either inhibits or 
stimulates cardiac hypertrophy (Zhu et al., 2003). 
Moreover, it remains unclear whether AT2R 
modulates NF-κB activation mediated by AT1R 
with angiotensin II. How, then, does HSP90, as a 
molecular chaperone involved in other proteins’ 
folding, stability, and maturation, actively regulate 
angiotensin II-induced NF-κB activation? Although 
HSP90 typically is described as protein-folding 
machinery, it also is implicated in the regulation of 
cellular signaling and the cell cycle progression 
(Brown et al., 2007). HSP90 also plays a key role 
in inflammatory and immune responses such as 
NF-κB and Janus kinase (JAK)-signal transducer 
and activators of transcription (STAT) pathway 
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(Madrigal-Matute et al., 2010). Some studies 
indicate that angiotensin II increases the HSP90 
level, inducing inflammatory and oxidative stress in 
vascular smooth muscle cells and brain micro-
vessels from spontaneously hypertensive rats (Li 
et al., 2005; Zhou et al., 2005), suggesting that 
HSP90 actively regulates angiotensin II-responsive 
signaling pathways. However, our results show 
that, HSP27 and HSP70 accumulated significantly 
after the cardiac cells had been incubated with 
angiotensin II for 24 h, but they had little or nothing 
to do with the HSP90 level (data not shown). It 
thus seems that angiotensin II-induced cellular 
hypertrophy is regulated by a change in the status 
of HSP90’s interactions with other proteins, rather 
than its expression, at least in cardiac cells. 
Indeed, as Figure 3C shows, interaction between 
HSP90 and IKKα /β  increased markedly in 
angiotensin II-treated cells. Thus, it is tempting to 
assume that, under normal conditions, HSP90 
remains in release from other proteins, but, when 
cells are stimulated with angiotensin II, HSP90 
might associate with other target proteins such as 
IKKα /β , leading to cardiac hypertrophy.
    Recently, HSP90 has become a new drug target 
for several diseases (Solit and Chiosis, 2008). In 
our results, HSP90’s interaction with the IKK 
complex might be necessary for IKK’s stability and 
activity, thereby activating the NF-κB pathway in 
angiotensin II-induced cardiac hypertrophy. So, 
HSP90 modulators might be potential candidates 
for new therapeutics to treat cardiac hypertrophy. 
Although some evidence has suggested HSPs’ 
roles in the NF-κB cascade, our data provide the 
first proposal on the crosstalk between HSP90 and 
the IKK complex-NF-κB cascade in the modulation 
of cardiac cell hypertrophy induced by angiotensin 
II. 
Methods
Materials 
Angiotensin II was purchased from Sigma (St. Louis, MO). 
Anti-HSP90, Anti-NF-κB p65, anti-IκBα, anti-IKKα/β, anti- 
cdc37, and anti-histone H1 antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti- 
phospho-IκBα (ser32) and anti-phospho-IKKα/β (Ser180/ 
181) antibodies were purchased from Cell Signaling 
(Beverly, MA). Anti-HSPα and anti-HSPβ antibodies were 
purchased from Assay Designs (Ann Arbor, MI). Hor-
seradish peroxidase-conjugated secondary antibodies and 
enhanced chemiluminescence detection system were 
obtained from Santa Cruz Biotechnology, and Amersham 
Biosciences (Uppsala, Sweden), respectively. Geldana-
mycin, 17-Allylaminogeldanamycin (17-AAG) and KNK437 
(Hsp70 inhibitor) were purchased from Calbiochem (San 
Diego, CA).
Cell culture
Rat neonatal ventricular cardiac myocytes were prepared 
as described previously with minor modifications (De Windt 
et al., 1997). All animal procedures were carried out 
according to a protocol approved by the Yonsei University 
Animal Care Committee. Heart from neonatal (1-2 days 
old) Sprague-Dawley rat was excised, and washed with 
phosphate-buffered saline (PBS) and minced. The minced 
myocardial tissues were incubated with 0.1% collagenase 
type II (Gibco, Grand Island, NY) with PBS. After digestion 
for 10 min, the cells were collected by centrifugation and 
resuspended in α-MEM containing 10% fetal bovine serum 
(FBS) and 100 U/ml penicillin/ streptomycin. Cells were 
pre-plated for 1 h at 37oC in CO2 incubator to allow 
removal of fibroblasts. Unattached cardiac myocytes were 
plated in gelatin coated dishes and incubated for 24 h. 
Measurement of [3H]leucine incorporation
[3H]Leucine incorporation was measured as described 
previously (Nozato et al., 2000). Cells were grown in 
24-well plates with serum-free medium for 24 h. Cells were 
then treated with angiotensin II for 24 h after pretreatment 
with or without inhibitor. The cells were pulsed with 1 
μCi/ml of [3H]leucine (Amersham Biosciences) during the 
last 4 h before harvest. After being washed with PBS, cells 
were treated with 5% trichloroacetic acid for 30 min and 
then washed with PBS. Finally, cells were solubilized in 
500 μl of 1 N NaOH. After neutralization with 0.5 N HCl, an 
aliquot was taken to determine the incorporated radio-
activity using liquid scintillation counter, Beckman LS 3801 
(Beckman, Fullerton, CA).
Measurement of protein and DNA content
The cells were washed with ice-cold PBS and lysed in 0.3 
M NaOH. For the protein content analysis, the cell extract 
was assayed by bicinchoninic acid reagent system (BCA 
assay kit, Sigma). For measurement of DNA concentration, 
the cell extract was treated with NaOH and then 
neutralized. Samples were incubated with 1.5 μM of 
Hoechst 33258 for 15 min in a darkroom. The Hoechst 
33258-labeled DNA was quantified using spectrofluore-
meter Victor 3 (Perkin-Elmer, Waltham, MA) with excitation 
at 355 nm and the emission at 460 nm.
Measurement of cell surface area
In the experiment of cell surface area measurement, cells 
were incubated with FITC-conjugated β-tubulin antibody 
(Sigma). The cells were photographed, and the surface 
area was analyzed using NIH image software.
Immunocytochemistry
Cells were plated in the 4-well slide chamber (Nalge Nunc, 
Rochester, NY) and grown with serum-free medium for 24 
h. Cells were fixed with 4% paraformaldehyde, and then 
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after the washing with PBS containing 0.2% NP-40, cells 
were blocked with 10% goat serum-containing PBS and 
incubated with anti-atrial natriuretic factor antibody (Pe-
ninsula Labs, San Carlos, CA). Cells were incubated with 
FITC-conjugated secondary antibody. Photographs of cells 
were taken using immunofluorescence microscopy (Olym-
pus, Melville, NY). 
NF-κB luciferase activity assay
Cells were transfected with NF-κB/luciferase reporter 
vector (pNF-κB/LUC, BD Biosciences, San Jose, CA). The 
pcDNA3.1/lacZ was also co-transfected to cells as an 
internal control of transfection efficiency detection. After 3 
h, the cells were grown overnight in fresh media. And then 
cells were starved and exposed to angiotensin II with or 
without inhibitor. The luciferase activity was determined 
using Luciferase Reporter Assay Kit (BD Biosciences). The 
activity of the NF-κB reporter luciferase was standardized 
to that of β-galactosidase activity.
Nuclear protein extraction
Nuclear extracts were prepared as described previously 
(Kang et al., 2001). Briefly, cells were washed, and then 
scraped with PBS, and centrifuged at 3,000 rpm at 4oC. 
The pellets were suspended in 10 mM Tris (pH 8.0) with 
1.5 mM MgCl2, 1 mM DTT, 0.1% NP-40 and incubated on 
ice for 15 min. Nuclei were separated from cytosol by 
centrifugation at 12,000 rpm at 4oC for 15 min. The 
cytosolic supernatants were removed, and the precipitated 
pellets were suspended in 10 mM Tris (pH 8.0) containing 
100 mM NaCl and stored on ice for 30 min. After agitation 
for 30 min at 4oC, the lysate was centrifuged at 12,000 rpm 
at 4oC, and the supernatant was collected. The nuclear 
protein concentration was determined using Bradford 
protein assay kit (Bio-Rad, Hercules, CA). 
SDS-PAGE and immunoblot analysis
Cells lysate was centrifuged at 12,000 g for 20 min at 4oC. 
Protein samples were separated in a 12% SDS- 
polyacrylamide gel and electrotransferred to polyvinylidene 
difluoride membranes. The membranes were washed with 
tris-buffered saline (TBS) and blocked by incubation with 
5% nonfat dry milk in TBS for 1 h. The membranes were 
incubated with specific primary antibodies for 1 h. After 
washing, membranes were incubated with horseradish 
peroxidase-conjugated secondary antibody and then 
detected with enhanced chemiluminescence detection 
solution. 
Immunoprecipitation assay
Cells were washed with PBS and lysed in a lysis buffer 
(Cell signaling). Cell lysates were incubated with antibody 
for 2 h at 4oC on a rotating plate. Precipitation was carried 
out with protein A/G agarose plus (Santa Cruz Bio-
technology). Samples were separated by SDS-PAGE and 
subjected to immunoblot analysis.
HSP90 siRNA transfection 
Rat HSP90 siRNA oligonucleotides were designed and 
synthesized from Genolution Pharmaceuticals (Seoul, 
Korea) as follows; HSP90α siRNA sequences, 5'-GCA-
GAAAUUGCCCAGUUAA-3', 5'-GCUGCACAUUAAUCUC-
AUU-3' and 5'-GUGGAUACUGGCAUUGGAA-3'; HSP90β  
siRNA sequences, 5'-GAUCCUCACCUCA AAGAA-3', 5'- 
GAAGGAGAUCAGUGAUGAU-3' and 5'-GGAUGACAGC-
GGCAAAGAU-3'. Cells were transfected with the pool of 
six HSP90 siRNAs (5 nM each) using Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA). After 48h of 
transfection, the levels of HSP90α and HSP90β were 
analyzed with anti-HSP90α and anti-HSP90β antibodies. 
A scrambled siRNA-A (Santa Cruz Biotechnology) was 
used as control.
Statistical analysis
Data are expressed as means± S.E. Statistical com-
parisons were performed by one-way analysis of variance 
and Student’s t-test. Differences were considered sig-
nificant at P＜ 0.05.
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